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Estimation of the prognosis of resectable pancreatic ductal adenocarcinoma (PDAC) cur-
rently relies on tumour-related factors such as resectionmargins and on lymph-node ratio
(LNR) both inconveniently available only postoperatively. Our aim was to assess the accu-
racy of preoperative laboratory data in predicting PDAC prognosis.
Methods
Collection of laboratory and clinical data was retrospective from 265 consecutive patients
undergoing surgery for PDAC at Helsinki University Hospital. Cancer-specific survival
assessment utilized Kaplan-Meier analysis, and independent associations between factors
were by the Cox regressionmodel.
Results
During follow-up, 76% of the patients died of PDAC, with a median survival time of 19.6
months. In univariate analysis, CRP, albumin, CEA, and CA19-9 were significantly associ-
ated with postoperative cancer-specific survival. In multivariate analysis, taking into account
age, gender, LNR, resectionmargins, tumour status, and adjuvant chemotherapy, the pre-
operative biomarkers independently associated with adverse prognosis were hypoalbumi-
nemia (< 36 g/L, hazard ratio (HR) 1.56, 95% confidence interval (CI) 1.10–2.19, p = 0.011),
elevated CRP (> 5 mg/L, HR 1.44, 95%CI 1.03–2.02, p = 0.036), CEA (> 5 μg/L, HR 1.60,
95%CI 1.07–2.53, p = 0.047), and CA19-9 (555 kU/L, HR 1.91, 95%CI 1.18–3.08, p =
0.008).
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Conclusion
For patients with resectable PDAC, preoperative CRP, along with albumin and tumour
markers, is useful for predicting prognosis.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is worldwide the fourth most common cause of
cancer death. It has an appalling 5-year overall survival rate of< 8% [1,2], and the only possi-
bility of cure is early radical surgery. Unfortunately, less than 10% of the patients are diagnosed
at a localized stage due to this cancer’s tendency to metastasize aggressively; even at its localized
stage, the 5-year survival rate is only 10–27% [1–3]. Moreover, pancreatic surgery itself is asso-
ciated with rather highmorbidity and mortality. Factors predicting the survival of pancreatic
cancer patients include TNM stage, resectionmargin, lymph-node ratio (LNR,metastatic
lymph nodes divided by number of lymph nodes analysed), vascular invasion, and differentia-
tion grade, each of these, however, typically revealed only during or after surgery [4–6].
Nowadays, evidence is increasing as to an association between cancer progression and
inflammation [7–9]. A cancer-related systemic inflammatory response (SIR), indicated by ele-
vated concentrations of circulating acute phase proteins such as C-reactive protein (CRP), is in
various cancer forms associated with worse prognosis [10–12]. In pancreatic cancer, the associ-
ation betweenCRP and prognosis has been under study mostly in patients receiving palliative
chemotherapy or in small patient groups [13,14]. Albumin is the most abundant protein in
human serum. Low concentrations of serum albumin (hypoalbuminemia) indicates poor nutri-
tional status and low performance status but albumin may also decrease due to many other
conditions such as systemic inflammation [15].
The Glasgow prognostic score (GPS), originally developed in a cohort of patients with non-
small cell lung cancer, combines elevated CRP and low albumin values to estimate prognosis
[16]. Later, because some studies failed to show hypoalbuminemia to be an independent pre-
dictor of survival, the GPS was modified by emphasizing elevated CRP [17]. This modified
Glasgow prognostic score (mGPS) predicts cancer survival independently of tumour site [18].
The biomarker most commonly serving for diagnosis, follow-up, and prognostic evaluation
of pancreatic cancer is the serum tumour marker CA19-9 [19–22]. Carcinoembryonic antigen
(CEA) at diagnosis has a lower sensitivity and specificity for PDAC than does CA19-9 [22].
The aim of this study was to evaluate preoperative CRP and albumin in the estimation of
postoperative survival of patients with resectable PDAC. We compared these markers with
prognostic clinico-pathological characteristics and tumour markers. Improving the accuracy of
preoperative estimation of prognosis could aid in the selection of patients for surgery, espe-
cially in borderline cases.
Patients andMethods
We collected data from all 292 patients undergoing surgery for histologically verified pancre-
atic ductal adenocarcinoma (PDAC) at Helsinki University Hospital (HUH) between 1 Janu-
ary, 2000 and 31 March, 2013. A pathologist specialized in pancreatology has retrospectively
re-examined the slides with tumour specimens to verify the diagnosis, and to determine the
resectionmargin, when possible. Patients undergoing emergency surgery, those who died of
surgery-related complications, and those with ongoing infection, auto-immune disease, or
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immunosuppressive medication at the time of surgery, totalling 7, were excluded.We included
only patients undergoing surgery with curative intent and excluded the 20 patients whose sur-
gery revealedmetastatic spread or otherwise unresectable disease. The operations included dis-
tal pancreatic resection,Whipple-Kausch pancreaticoduodenectomy, pylorus-preserving
pancreaticoduodenectomy, and total pancreatectomy. Some patients received pre- and postop-
erative oncological treatment: preoperatively either gemcitabine with or without radiotherapy,
postoperatively gemcitabine, capecitabine, or a combination of gemcitabine and cisplatin or
capecitabine either as adjuvant therapy or later as palliative treatment for those patients who
had no adjuvant therapy but received palliative chemotherapy only after disease progression
was found postoperatively (Table 1). We collected data on case-report forms linked to an
Access1 database and converted it for analysis with the IBM Statistical Package for Social Sci-
ences (SPSS) Statistics 22. This study applied the ReportingRecommendations for Tumour
Marker Prognostic Studies (REMARK) criteria [23]. The end of follow-up was 31 March 2015,
with a minimum follow-up of 2 years.
Patient characteristics
Patients totalled 265 (characteristics are summarized in Table 1). Mean age for the operation
was 65 years (standard deviation (SD) ± 8.6), ranging from 39 to 86 years. Median overall fol-
low-up was 25.2 months. At the end of follow-up, 202 (76%) study patients had died of PDAC,
with a median survival of 19.6 months (range: 1.1 month to 9.3 years), 53 (20%) patients were
still alive (follow-up range: 2.0 to 14.1 years), and 10 (4%) patients had died of other causes.
High-sensitivityCRP
CRP levels were determined from 230 plasma samples prospectively collectedwith informed
consent for research purposes before surgery and stored frozen at -80°C until assayed [24].
Plasma CRP was determined by a time-resolved immunofluorometric assay performed in
microtitration plates using a monoclonal CRP antibody (anti-hCRP, code 6405, Medix Bio-
chemica, Espoo, Finland). Because CRP is a pentamer, the same antibody served to capture
CRP and served also as a tracer. The antibody was diluted to a concentration of 5 μg/ml in
phosphate-buffered saline (PBS) and coated onto the solid phase by incubation of 200 μl in
each well overnight. The same antibody, labelled with europium chelate, served as a tracer. Cal-
ibrators (Labquality, Helsinki, Finland) covered the concentration range 3 μg/L–300 μg/L. The
samples were diluted 100-fold before the assay; thus the measuring range was 0.3 mg/L–30 mg/
L. Imprecision was< 10% over the whole assay range.
Other laboratoryanalyses
All laboratorymethods, except for the CRP assay, were standard methods of the clinical labora-
tory of HUH. In the statistical analyses we used predominantly standard cut-off values recom-
mended by the manufacturer and used in clinical practice in our hospital. Hypoalbuminemia,
elevated CRP, and CA19-9 we further divided, in order to explore whether survival worsens
with greater divergence from the normal values. Laboratory data collected from patient records
included leukocytes (n = 265), albumin (259), platelets (262), and bilirubin (262), available up
to 5 days preoperatively, as well as CA19-9 (255) and CEA (252), which were determined up to
2 months preoperatively, always using the latest value available before the day of surgery. The
vast majority of laboratorymeasurements were determined the day before surgery. According
to Finnish guidelines, any albumin level< 36 g/L was considered hypoalbuminemic, except
when calculating the GPS.
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Table 1. Patient characteristics and survival time.
Total n = 265 n (%) Median survivalmonths (95%CI) p
Sex
Male 150 (56.6) 25.4 (18.9–31.9) 0.453
Female 115 (43.4) 26.9 (23.8–30.0)
Age
< 60 years 70 (26.4) 27.4 (19.8–35.0) 0.177
60–64 years 57 (21.5) 25.7 (17.4–34.1)
65–70 years 59 (22.3) 26.3 (16.8–35.9)
> 70 years 79 (29.8) 26.1 (19.2–32.9)
Margin involvement
R0 207 (78.1) 30.0 (25.1–35.0) < 0.001
R1 42 (15.8) 18.3 (7.6–28.9)
Data missing 16 (6.0)
T status
T1 21 (7.9) 27.2 (15.9–38.5) 0.003
T2 64 (24.2) 36.0 (22.3–49.7)
T3 166 (62.6) 22.0 (17.7–26.3)
T4 8 (3.0) 14.7 (7.4–22.0)
Data missing 6 (2.3)
Nodalmetastases
N0 94 (35.5) 33.6 (30.4–36.8) 0.001
N1 169 (63.8) 21.5 (17.3–25.7)
Data missing 2 (0.8)
LNR
N0 94 (35.5) 33.6 (30.4–36.8) < 0.001
N1, 0.2 123 (46.4) 25.7 (17.9–33.6)
N1, > 0.2 42 (15.8) 13.6 (7.7–19.4)
Data missing 6 (2.3)
Tumour location
Head 230 (86.8) 26.0 (21.8–30.1) 0.734
Tail 13 (4.9) 34.1 (9.4–58.8)
Body 19 (7.2) 36.0 (10.3–61.7)
Data missing 3 (1.1)
Tumour size
 30 mm 135 (51.0) 30.1 (24.8–35.4) 0.007
> 30 mm 120 (45.0) 20.5 (15.6–25.4)
Data missing 10 (4.0)
ERCP and stenting
No ERCP 89 (33.6) 27.1 (16.6–37.6) 0.640
ERCP + stent 169 (63.8) 26.4 (22.2–30.7)
Data missing 7 (2.6)
Preoperative chemo-/radiotherapy
None 218 (82.3) 25.7 (20.8–30.6) 0.573
Yes 46 (17.4) 30.0 (23.7–36.4)
Data missing 1 (0.4)
Postoperative chemo-/radiotherapy
None 86 (32.5) 21.9 (14.5–29.3) 0.058
Adjuvant 139 (52.5) 30.1 (24.1–36.0)
(Continued)
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The Glasgow prognostic score
When calculating the GPS, either an elevated CRP (> 10 mg/L) or a low albumin level (< 35 g/
L) received a score of 1. Patients having both elevated CRP and hypoalbuminemia scored GPS
2, and those with normal CRP< 10 mg/L and albumin> 35 g/L scored GPS 0 [16]. We also
calculated the modifiedGlasgow prognostic score (mGPS), according to which, mGPS scored 0
if CRP was normal (< 10 mg/L), irrespective of albumin level; mGPS score 1 represented ele-
vated CRP (> 10 mg/L), and score 2 represented elevated CRP combined with low albumin
[18]. If either of these values was missing, we excluded that patient from GPS- and mGPS
analysis.
Statistics
We conducted statistical analyses with IBM SPSS 22, and calculated associations between con-
tinuous variables by two-tailed Spearman’s correlations, normality by the Kolmogorov-Smir-
nov test, and differences in distributions by the Mann-Whitney U- or the Kruskall-Wallis test.
The Jonckheere-Terpstra test allowed calculation of the significance of differences in medians
of laboratory tests by survival time (ordinal scale). Survival time was defined from pancreatic
surgery to disease-specificdeath; if no events had occurred, each patient was censored at the
last follow-up date. Kaplan-Meier analysis and the log-rank test served for survival estimation,
and the Cox proportional hazards model for the multivariate analysis. We included in the mul-
tivariate analysis variables with a p value< 0.1 in univariate analysis, and also the clinically sig-
nificant variables age and sex. The multivariate analyses included only those 189 patients with
no missing values. Interactions were considered, but no significant interactions emerged. A p
value< 0.05 indicated the limit for statistical significance.
Ethics
This study followed the ethical, medical, and legal guidelines of Finland and the Declaration of
Helsinki. Approval came from the Helsinki University Hospital Ethics Committee and the
National SupervisoryAuthority for Welfare and Health (Valvira). Blood samples for research
purposes were taken only after written informed consent from the patients. The guidelines of
HUH and National Data Protection ensured the confidentiality of patient information.
Results
Laboratory results
A summary of preoperative laboratory results appears in Table 2 and their associations with
clinico-pathological features in Table 3. Median preoperative CRP was 3.7 mg/L (inter quartile
Table 1. (Continued)
Total n = 265 n (%) Median survivalmonths (95%CI) p
Palliative 34 (12.8) 23.9 (15.4–32.5)
Data missing 6 (2.3)
Cause of death
Pancreatic cancer 202 (76.2) –
Other 10 (3.8) –
Alive 53 (20.0) –
Median survival time was assessed by Kaplan-Meier analysis and significance by log-rank test.
doi:10.1371/journal.pone.0163064.t001
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Table 2. Preoperative biomarkers' association withmedian survival time and the univariate analysis.
Factors n Median survivalmonths (95%CI) p(survival time) HR (95%CI) p(HR) Median (IQR)
CRP 3.7 (8.4)
 5.0 mg/L 130 31.8 (25.7–37.9) < 0.001 1 < 0.001
5.1–15.0mg/L 58 26.3 (21.5–31.2) 1.4 (1.02–2.04) 0.040
> 15.0 mg/L 42 14.4 (4.4–24.4) 2.3 (1.6–3.3) < 0.001
Missing 35
Albumin 37.0 (4.3)*
 30.0 g/L 16 10.0 (2.9–17.0) < 0.001 3.0 (1.8–5.0) < 0.001
30.1–35.9 g/L 83 18.1 (13.1–23.0) 1.6 (1.2–2.2) 0.001
 36.0 g/L 160 31.7 (26.6–36.8) 1 < 0.001
Missing 6
CA19-9 133.5 (501.0)
 37 kU/L 81 33.5 (25.9–41.1) < 0.001 1 < 0.001
38–554 kU/L 114 26.0 (20.0–32.0) 1.5 (1.01–2.0) 0.022
 555 kU/L 60 16.1 (7.4–24.7) 2.1 (1.5–3.1) < 0.001
Missing 10
CEA 2.7 (2.7)
 5.0 μg/L 205 27.4 (23.7–31.1) 0.016 1
> 5.0 μg/L 47 14.4 (22.7–30.0) 1.5 (1.1–2.2) 0.017
Missing 13
Bilirubin 16.0 (25.0)
 20 g/L 154 26.4 (22.7–30.1) 0.153 1
> 20 g/L 108 23.0 (14.6–31.5) 1.2 (0.9–1.6) 0.154
Missing 3
Platelets 235.5 (101.0)
150–360 E9/L 211 26.9 (23.5–30.3) 0.642 1 0.644
<150 E9/L 21 23.9 (0.0–54.5) 0.8 (0.5–1.4) 0.378
>360 E9/L 30 20.4 (5.1–35.6) 1.1 (0.7–1.6) 0.817
Missing 3
Leukocytes 6.1 (2.7)
3.4–8.2 E9/L 204 26.3 (22.2–30.5) 0.685 1 0.686
< 3.4 E9/L 8 23.9 (0.0–50.9) 0.8 (0.4–1.9) 0.669
> 8.2 E9/L 53 25.5 (16.5–34.4) 1.1 (0.8–1.6) 0.476
Missing 0
GPS –
0 136 31.7 (25.9–37.5) < 0.001 1 < 0.001
1 59 21.5 (13.6–29.4) 1.7 (1.2–2.4) 0.004
2 30 14.4 (2.8–26.0) 2.4 (1.6–3.6) < 0.001
Missing 40
mGPS –
0 172 29.6 (25.1–34.0) < 0.001 1 < 0.001
1 23 24.9 (17.0–32.8) 1.6 (0.99–2.6) 0.053
2 30 14.4 (2.8–26.0) 2.2 (1.4–3.2) < 0.001
Missing 40
Abbreviations: HR, hazard ratio; CI, confidence interval; GPS, Glasgow prognostic score; mGPS, modifiedGlasgow prognostic score; IQR, inter quartile
range
*Mean albumin (standard deviation)
Preoperative biomarkers' association with median survival time (months) was assessed with Kaplan- Meier analysis. Univariate analysis of the hazard ratios
(HR) was by Cox regressionmodel.
doi:10.1371/journal.pone.0163064.t002
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range (IQR) 1.7–10.1 mg/L). Patients who died of PDAC had a higher median CRP 4.9 mg/L
(IQR 1.8–13.1 mg/L) than the median CRP of 1.9 mg/L (IQR 1.2–3.6 mg/L) (p< 0.001) of
patients alive throughout follow-up. Furthermore, the higher the CRP, the shorter the sur-
vival time (Table 3). CRP showed no association with T status, LNR, nor tumour size
(Table 3). Administration of neoadjuvant therapy had no significant association with CRP
(p = 0.538).
Mean preoperative albumin was 37.0 g/L (SD 4.3 g/L). The majority of patients had normal
albumin levels, whereas 38% had hypoalbuminemia (< 36.0 g/L). Albumin was associated with
patient age, T status, and tumour size (Table 3). Patients who died of PDAC had lower mean
albumin than did patients dying of other causes or alive at the end of follow-up; the shorter the
survival, the lower the mean albumin (p = 0.001) (Table 3).
CA19-9 (median 133 kU/L, IQR 21–526 kU/L) and CEA (median 2.7 μg/L, IQR 1.8–
4.4 μg/L) were associated with T status and tumour size (Table 3). Both tended to increase
with shorter survival time (p = 0.001). CA19-9 increased also with increasing LNR status
(p = 0.018) (Table 3). Additionally, bilirubin level and leukocyte and platelet counts were
analysed but showed no association with disease-specific survival in univariate analysis
(Table 3).
Table 3. Associationsof preoperative biomarkers with patient- and tumour-related factors.
CRP (mg/L) Albumin (g/L) Ca19-9 (kU/L) CEA (μg/L)
Median (IQR) p Mean (SD) p Median (IQR) p Median (IQR) p
Sex
Male 3.5 (8.2) 0.853 37.1 (4.5) 0.421 133.0 (511) 0.727 2.7 (3.1) 0.724
Female 4.4 (8.2) 36.7 (4.0) 129.5 (488) 2.7 (2.4)
Age
< 65 3.6 (7.2) 0.220 37.5 (4.4) 0.033 102.0 (452) 0.095 2.6 (3.2) 0.655
 65 3.9 (9.3) 36.4 (4.2) 140.0 (561) 2.7 (2.5)
T status
T1–T2 3.2 (6.5) 0.073 37.8 (4.1) 0.026 63.0 (222) 0.007 2.5 (2.3) 0.023
T3–T4 4.5 (9.5) 36.5 (4.4) 185.5 (558) 2.8 (2.9)
LNR
N0 3.1 (7.4) 0.652 37.0 (4.1) 0.499 79.0 (414) 0.018 2.7 (2.6) 0.109
N1, 0.2 3.6 (7.8) 36.9 (4.6) 129.0 (428) 2.7 (2.7)
N1, > 0.2 4.8 (12.2) 36.7 (4.1) 274.5 (1612) 3.2 (2.9)
Tumour size
 30 mm 3.23 (7.3) 0.072 37.4 (4.2) 0.018 65.5 (333) < 0.001 2.6 (2.3) 0.033
>30 mm 4.5 (11.7) 36.2 (4.4) 223 (839) 3.1 (3.4)
Cause of death
PDAC 4.9 (11.3) < 0.001 36.4 (4.4) 0.001 147.0 (570) 0.038 2.8 (2.6) 0.208
Other or alive 2.8 (3.5) 38.5 (3.5) 56.5 (301) 2.4 (2.5)
Survival time
< 3 months 19.5 (83.3) 0.001 30.3 (4.0) < 0.001 780 (3283) < 0.001 3.9 (3.1) 0.010
3–12months 6.2 (14.8) 35.9 (4.4) 336 (972) 3.4 (4.5)
12–24months 4.4 (7.8) 36.5 (3.9) 146 (606) 2.7 (2.0)
> 24 months 2.8 (6.6) 37.8 (4.1) 69 (362) 2.5 (2.3)
PDAC, pancreatic ductal adenocarcinoma; LNR, lymph-node ratio; IQR, inter quartile range; SD, standard deviation
Significances were determined with the Mann-Whitney U or the Jonckheere-Terpstra test (abnormaldistribution) or with the T-test and One-Way ANOVA for
linear contrasts (normal distribution).
doi:10.1371/journal.pone.0163064.t003
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Tumour-related factors
Median tumour size was 30 mm, ranging from 5 mm to 90 mm (255 tumours). Resectionwith
radical> 1 mmmargins (R0) was successful in 207 (78%) cases (data on resectionmargins
were missing from 16 pathology reports). Lymph nodemetastases occurred in 169 (64%)
patients, and 94 (36%) were lymph-node negative (2 patients had no lymph-node examina-
tion). Median LNR was 0.06 (IQR 0.00–0.16).
Univariate analyses
Univariate associations of clinico-pathological features and laboratory results with survival are
presented in Tables 1 and 2, and survival curves in Fig 1. In Kaplan-Meier analysis, median sur-
vival time for patients with CRP 5.0 mg/L or lower was 31.8 months (95% CI 25.7–37.9) com-
pared to 23.9 months (95% CI 19.5–28.4, p< 0.001) for those at over 5.0 mg/L (HR 1.7, 95%
CI 1.3–2.3, p< 0.001). Patients suffering from hypoalbuminemia (< 36 g/L) had a significantly
shorter survival time of 18.0 months (95% CI 12.7–23.2) compared to 31.7 months (95% CI
26.6–36.8) (p< 0.001) for those with normal albumin level (HR 1.8, 95% CI 1.3–2.4,
p< 0.001).
We assessed the impact of both the GPS and the mGPS (emphasizing elevated CRP) in
prognosis evaluation for resectable PDAC. Median survival time decreased significantly with
increasing scores for both GPS and mGPS, although the hazard ratio (HR) 1.6 for mGPS 1 was
not statistically significant (p = 0.053). The HR for GPS 1 was 1.7 (p = 0.004) and for GPS 2
was 2.4 (p< 0.001) (Table 2, Fig 1).
Elevated concentrations of CEA (> 5 μg/L), and CA19-9 (> 38 kU/L) were significantly
associated in univariate analyses with worse survival (Table 2, Fig 1). Of the clinico-pathologi-
cal factors, tumour size, radical resectionmargins, T status, nodal metastases, and LNR associ-
ated significantly with worse survival (Table 1).
Multivariate analyses
Regarding gender, age, T status, LNR, adjuvant therapy, tumour size, and resection radicality,
the biomarkers that were independently associated with adverse prognosis in multivariate anal-
ysis were low albumin (< 36 g/L, p = 0.011), elevated CRP (> 5 mg/L, p = 0.036), CEA
(> 5 μg/L, p = 0.047), and CA19-9, but the latter only when elevated 15-fold above its reference
limit ( 555 kU/L, p = 0.008) (Table 4). Administration of adjuvant therapy, R0 resectionmar-
gins, and low LNR (N0 and LNR 0.2) were independently associated with more favourable
prognosis. In a multivariate model including otherwise the same variables as in Table 4 but
using continuous values for laboratory results, CRP (lg10) (HR 1.53, CI 95% 1.07–2.17,
p = 0.018), CA19-9 (lg10) (HR 1.28, CI 95% 1.05–1.56, p = 0.015), and albumin (HR 0.95, CI
95% 0.91–0.99, p = 0.020) each showed a linear association with survival.
In multivariate analysis taking into account gender, age, T status, LNR, adjuvant therapy,
tumour size, resection radicality, CA19-9, CEA, and GPS, a score of GPS 1 was not significantly
associated with survival, whereas GPS 2 raised the HR significantly to 2.2 compared to HR for
GPS 0 (p = 0.001) (Table 5). These results were similar to those of mGPS, with the same factors
remaining statistically significant.
Discussion
In this large retrospective study, we show that in surgically treated pancreatic ductal adenocar-
cinoma (PDAC), preoperatively increased levels of plasma CRP independently predict worse
postoperative prognosis. Additionally, low serum albumin, elevated tumour markers CA19-9
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and CEA, as well as a larger lymph-node ratio (LNR, N0 / 0.2 /> 0.2), no adjuvant chemo-
therapy, and R1 resectionmargin status were associated independently with a grim postopera-
tive outcome.
The relationship of inflammation and cancer progression has intrigued scientists for the
past two decades, yet the underlying reason for the unfavourable prognosis of cancer-related
SIR remains partially unexplained [25,26]. Cancer-induced inflammation releases increased
levels of circulating inflammatory cytokines such as interleukin 6 and TNFα, both of which ini-
tiate SIR. Cancer-related SIR correlates with symptoms associated with cancer such as fatigue,
fever, weight loss, pain, and depression [27,28]. SIR may be related even to variability in the
response to and the toxicity of cancer chemotherapy [25].
Fig 1. Survival curves.Effects of preoperative C-reactive protein (CRP), albumin, Glasgow prognostic score (GPS),modified
GPS (mGPS),CA19-9, and CEA on disease-specific survival in patients with surgically treated pancreatic cancer. Survival
curves (survival time in months after surgery)by Kaplan-Meier analysis and significance by log-rank test.
doi:10.1371/journal.pone.0163064.g001
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Our results support those of other studies concerning the assumption that SIR is detrimen-
tal to PDAC patients even if the tumour is resected radically [29–31]. Elevated CRP showed no
significant association with those tumour-related factors typically associated with survival
(tumour size, T status, LNR). This may suggest that SIR development is not directly connected
Table 4. Multivariate model considering clinically and statistically importantpatient characteristics
and preoperative biomarkers (n = 189).
Factor Description HR (95%CI) p value
Age (years) <65/65 1.11 (0.78–1.58) 0.554
Sex Male/female 1.36 (0.96–1.95) 0.083
Tumour size (mm) 30/>30 1.04 (0.71–1.51) 0.842
T status T1–2/T3–4 1.27 (0.86–1.88) 0.233
Adjuvant therapy Yes/No 1.81 (1.25–2.61) 0.002
Margin involvement R0/R1 1.92 (1.24–2.97) 0.003
LNR (0) N0 1 < 0.001
LNR N1,0.2 1.94 (1.30–2.88) 0.001
LNR N1, >0.2 3.41 (1.96–5.95) < 0.001
Albumin (g/L) 36/<36 1.56 (1.10–2.19) 0.011
CRP (mg/L) 5 />5 1.44 (1.03–2.02) 0.036
CEA (μg/L) 5/>5 1.60 (1.07–2.53) 0.047
CA19-9 (kU/L) 37 1 0.015
CA19-9 (kU/L) 38–554 1.09 (0.73–1.69) 0.633
CA19-9 (kU/L) 555 1.91 (1.18–3.08) 0.008
HR, hazard ratio; CI, confidence interval; LNR, lymph-node ratio
All these variables were included in one Cox proportional hazardmodel.
doi:10.1371/journal.pone.0163064.t004
Table 5. Multivariate model consideringGPS and tumourmarkers as well as clinically and statistically
importantpatient characteristics (n = 189).
Factor
Description HR (95%CI) p value
Age (years) <65/65 1.23 (0.80–1.60) 0.500
Sex Male/female 1.36 (0.95–1.95) 0.096
Tumour size (mm) 30/>30 1.04 (0.72–1.50) 0.838
T status T1-2/T3-4 1.32 (0.90–1.95) 0.159
Adjuvant therapy Yes/No 1.84 (1.28–2.65) 0.001
Margin involvement R0/R1 2.02 (1.32–3.10) 0.001
LNR (0) N0 1 < 0.001
LNR N1,0.2 1.91 (1.29–2.85) 0.001
LNR N1, >0.2 3.40 (1.97–5.87) < 0.001
CEA (μg/L) 5/>5 1.46 (0.93–2.30) 0.100
CA19-9 (kU/L) <555/555 1.82 (1.22–2.72) 0.003
GPS 0 1 0.006
GPS 1 1.21 (0.82–1.79) 0.333
GPS 2 2.18 (1.35–3.50) 0.001
HR, hazard ratio; CI, confidence interval; LNR, lymph-node ratio; GPS, Glasgow prognostic score
All these variables were included in one Cox proportional hazardmodel.
doi:10.1371/journal.pone.0163064.t005
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to these tumour-related factors. Circulating acute-phase proteins can also increase due to other
conditions more common than cancer, ones such as acute infections and auto-immune dis-
eases. It is thus important to separate cancer-related SIR from these conditions, the ones which
we took into account as our exclusion criteria. An advantage of our study is the detailed and
reliable clinico-pathological information available from all patients, including medical history,
tumour stage, and histological type.
One of the most validated prognostic scores based on laboratory variables is the Glasgow
prognostic score (GPS) combining high CRP and low albumin [16]. In one large cohort study
exploring several cancer types, hypoalbuminemia alone was associated with worse survival in
some other cancer types but not with hepatopancreaticobiliary cancers, and their conclusion
was that the modifiedGPS (mGPS), emphasizing elevated CRP, is a more universal prognostic
score than is the GPS [17]. In our study, preoperative hypoalbuminemiawas independently
associated with worse survival, thus supporting the use of GPS instead of mGPS for resectable
PDAC. It associated also with tumour size and T-status. Hypoalbuminemia as an independent
prognostic factor in resectable PDAC has produced conflicting results, with some showing a
similar association [29,32], but others showing contradictory results [33]. Cachexia and poor
performance status are common in PDAC patients and they are associated with worse survival
and hypoalbuminemia. However, all the patients in the present study were preoperatively eval-
uated to be fit for surgery (the Karnofsky Performance Status Scale of 60 [34]).
Besides CRP and hypoalbuminemia, elevation of the tumour markers CA19-9 and CEA cor-
related independently with worse prognosis [20,35]. Additionally, tumour-related factors are
strong mediators in the prognostic evaluation of surgically treated PDAC [5,36]. Multivariate
analysis showed that lymph-node ratio and resectionmargin status associated strongly with
survival. T-status and tumour size were significant factors in univariate analysis but not in mul-
tivariate analysis. This might result from selection bias in our study, as patients with a resect-
able disease tend to have smaller tumours than do pancreatic cancer patients on average.
Additionally, adjuvant therapy was associated with more favourable prognosis. The obvious
prognostic disadvantage of the tumour-related factors is that they are available only during or
after surgery. Increasing evidence of the prognostic value of preoperative CRP, albumin, and
GPS support their utility for clinical decision-making in evaluation of postoperative survival,
possibly combined with tumour markers. In fact, recent international guidelines have acknowl-
edged the association between cancer-related SIR and PDAC survival, by recommendingmea-
surement of either mGPS or the neutrophil-to-lymphocyte ratio (NLR) in all patients
considered for PDAC resection [37]. Our study supports the routine analysis of CRP and albu-
min preoperatively of all patients with PDAC considered for surgical treatment as a part of the
general evaluation of prognosis. Further validation is necessary to make actual guidelines con-
cerning their use in clinical practice. In light of our study elevated CRP combined with hypoal-
buminemia and tumour markers might be helpful for selecting patients for surgery, especially
in borderline cases. These results also raise the question whether patients with preoperative SIR
would benefit from treatment with anti-inflammatory drugs or neoadjuvant therapy. This
could provide a new and interesting research field.
A limitation of our retrospective study was some missing laboratory results and incomplete
information in some pathology reports. Tumour grade in particularwas seldom reported for
earlier tumour samples and therefore underwent no analysis. Furthermore, because neutrophil
and lymphocyte counts had no routine analysis, we were unable to determineNLR, recently
proposed as a potential prognostic factor [14,33]. The present study is nonetheless one of the
largest on the association of preoperative biomarkers with the prognosis of surgically treated
PDAC.
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In conclusion, this large retrospective study of patients with resectable PDAC shows that
elevated CRP and hypoalbuminemia, as well as the GPS based on these parameters, were inde-
pendent prognostic markers, indicating that preoperative cancer-related SIR is predictive of
worse survival.
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